Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TWINSS extension study of iscalimab in Sjogren's syndrome
2020-001942-20Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of iscalimab in Sjögren's syndrome (2 arms), sponsored by Novartis. Primary endpoint: Incidence of treatment-emergent adverse events and serious adverse events. Started Sep 2020; status: completed.
02
Drugs
iscalimab
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on 2020-001942-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001942-20.